Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Diabetes Combos: Novo, Sanofi May Need New Treatment Paradigm To Match Products

Executive Summary

Stepwise approach of endocrinologists may have to change to maximize uptake of insulin/GLP-1 combinations.

You may also be interested in...



Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems

FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.

Sanofi's Adlyxin Merely Another Option For Type 2 Diabetes Treatments

After a long wait, lixisenatide has little to distinguish itself from the five GLP-1 products already on the market.

US FDA Oncology, Device Centers Developing Public Diagnostic Standards

Pilot program would get around the ‘one drug, one test’ policy, which has created intellectual property issues.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS057671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel